Citizens Jmp Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $152.00

Key Points

• Citizens Jmp cut its price target for Rhythm Pharmaceuticals to $152 (from $176) while maintaining a "market outperform" rating, implying roughly a 70.8% upside from the recent close; the Street consensus target is lower at about $133 with a "Moderate Buy" rating.
• Rhythm reported a Q4 beat (EPS loss of $0.73 vs. $0.79 expected) and revenue up 36.9% year‑over‑year, with management highlighting FY25 revenue growth (~+50% to $194.8M); the stock trades near $89 and has a ~$6.1B market cap.
• Clinical and regulatory risk is mixed: the EMANATE program had several substudies miss primary endpoints and Reuters reported the trial failed its main goal, raising uncertainty ahead of the PDUFA decision on March 20, although separate TRANSCEND and subgroup data showed supporting efficacy signals.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) had its target price dropped by analysts at Citizens Jmp from $176.00 to $152.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a "market outperform" rating on the stock. Citizens Jmp's price objective points to a potential upside of 70.77% from the stock's previous close.

Several other equities research analysts have also recently issued reports on the company. Royal Bank Of Canada assumed coverage on Rhythm Pharmaceuticals in a research note on Wednesday, February 18th. They set an "outperform" rating and a $145.00 target price for the company. Needham & Company LLC lowered their price target on Rhythm Pharmaceuticals from $139.00 to $130.00 and set a "buy" rating for the company in a report on Tuesday. UBS Group reissued a "buy" rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 17th. Guggenheim boosted their price objective on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a "buy" rating in a report on Friday, February 27th. Finally, HC Wainwright decreased their target price on shares of Rhythm Pharmaceuticals from $125.00 to $110.00 and set a "buy" rating on the stock in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Rhythm Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $133.00.

Rhythm Pharmaceuticals Stock Down 1.7%

Shares of Rhythm Pharmaceuticals stock traded down $1.50 during mid-day trading on Tuesday, hitting $89.01. The stock had a trading volume of 98,196 shares, compared to its average volume of 707,228. The firm has a 50-day moving average of $100.00 and a two-hundred day moving average of $102.91. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20. The firm has a market cap of $6.08 billion, a P/E ratio of -28.65 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The firm had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million. During the same quarter in the previous year, the company earned ($0.72) EPS. The business's revenue for the quarter was up 36.9% compared to the same quarter last year. Sell-side analysts expect that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the sale, the chief accounting officer directly owned 160 shares of the company's stock, valued at approximately $14,329.60. The trade was a 97.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of the business's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares in the company, valued at $11,190,445.12. This represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 27,267 shares of company stock valued at $2,719,955. Company insiders own 6.10% of the company's stock.

Institutional Trading of Rhythm Pharmaceuticals

Several hedge funds have recently made changes to their positions in RYTM. EverSource Wealth Advisors LLC grew its stake in shares of Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company's stock worth $28,000 after acquiring an additional 200 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company's stock valued at $29,000 after acquiring an additional 141 shares in the last quarter. SBI Securities Co. Ltd. raised its stake in shares of Rhythm Pharmaceuticals by 73.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company's stock valued at $37,000 after acquiring an additional 145 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company's stock valued at $35,000 after purchasing an additional 322 shares during the period. Finally, GAMMA Investing LLC grew its stake in Rhythm Pharmaceuticals by 48.6% during the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company's stock worth $39,000 after purchasing an additional 118 shares in the last quarter.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and FY25 growth: Rhythm reported robust FY25 revenue (+50% yr/yr to $194.8M) and a Q4 beat that management says sets the stage for an expanded opportunity if the FDA approves setmelanotide for acquired hypothalamic obesity (PDUFA March 20). SA: Q4 Beat & PDUFA
• Positive Sentiment: Analysts remain bullish despite lower price targets — Bank of America (PT cut to $139, buy), Morgan Stanley (PT cut to $136, overweight) and Needham (PT cut to $130, buy) still signal material upside vs. the current share level, supporting demand. Benzinga: Analyst Notes (BoA & MS) TickerReport: Needham
• Positive Sentiment: Post‑hoc subgroup benefit: Company press release and analyses indicate setmelanotide achieved statistically significant BMI reductions at 52 weeks in patients with heterozygous variants of POMC/PCSK1 and SRC1 (NCOA1) — a signal that could matter for narrower, high‑value indications or label strategy. GlobeNewsWire: EMANATE Topline
• Positive Sentiment: Supporting Phase 3 TRANSCEND data: Separate TRANSCEND results showed a clinically meaningful ~-16.4% mean BMI reduction, which investors view as supportive context for setmelanotide’s efficacy profile ahead of regulatory review. SA: TRANSCEND Context
• Neutral Sentiment: EMANATE trial transcript & analysis: A Seeking Alpha transcript and commentary provide detailed topline discussion and management remarks — useful for parsing nuances but not new data. SA: EMANATE Transcript
• Negative Sentiment: Primary endpoints missed in EMANATE substudies: The company acknowledged four EMANATE substudies did not meet pre‑specified primary endpoints, and Reuters reported the experimental obesity drug failed its main goal in the late‑stage trial — this raises regulatory and commercial execution risk. Reuters: Trial Miss

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.